Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Q4 2018 Earnings Conference Call - Final Transcript
Mar 12, 2019 • 05:00 pm ET
Ladies and gentlemen, greetings, and welcome to the Bellicum Pharmaceuticals Fourth Quarter and Full Year 2018 Financial Results. (Operator Instructions) As a reminder, this program is being recorded.
It is now my pleasure to introduce your host, Atabak Mokari, Chief Financial Officer. Thank you. You may begin.
Thank you. Good afternoon, everyone, and thank you for joining the call. With me today is Rick Fair, Bellicum's President and Chief Executive Officer; Bill Grossman, Chief Medical Officer; and Aaron Foster, Head of Research. Earlier this afternoon, Bellicum released financial results for the fourth quarter and full year ended December 31, 2018. If you have not received this release or if you would like to be added to the distribution list, you can do so on the Investor Relations page of the company's website.
As a reminder, today's conference call will include forward-looking statements made under the Private Securities Litigation Reform Act of 1995, including statements regarding our research and development plans, clinical trials, plans regarding regulatory filings, review and approval of our product candidates, commercialization expectations and our financial outlook. These forward-looking statements involve a number of risks and uncertainties and reflect our opinions only as of the date of this call. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. Actual results may differ from those indicated by these forward-looking statements due to numerous factors, including those discussed in the risk factors section of our Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission.
And now I'll turn the call over to Rick.
Richard A. Fair
Thanks, Atabak. Good afternoon, everyone, and thanks for joining us. I'm excited to share with you today the progress we've made across our pipeline of controllable cell therapies as well as our key objectives for 2019. On our call today, I'll provide an update and outline 2019 goals for our two strategic priorities, namely our GoCAR-T pipeline and rivo-cel. Before I do, I'll begin with a brief reflection on my time at Bellicum as context for our 2018 accomplishments and future prospects.
Over the last two years, we've made significant progress in strengthening our organization. We've recruited a new executive team with deep expertise. We've improved our capabilities across the company, in particular in clinical development. And we've instilled a patient-focused culture built on great science, performance and accountability. While Bellicum has always had exciting science and technology, we've worked hard to match that with great execution, progressing product candidates efficiently to and through the clinic.
The proof of these efforts is in the results. In 2018, we set a company record for achievement of our corporate goals and objectives, which included presentation of initial data from our BPX-601 study, progression of two preclinical dual-switch GoCAR-T programs with expected IND applications in 2019, completion of enrollment in our pediatric trials for rivo-cel and presentation of late interim analysis from these trials, initiation of launch